Skip to Content
  • Article
  • Open Access

16 November 2026

14 Pages

Effects of CDDO Derivatives (RTA 404, RTA dh404, and RTA 408) on Cell Proliferation, Apoptosis, and Oxidative Stress-Related Responses in Ishikawa Endometrial Cancer Cells

,
,
,
and
1
Graduate Institutes of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
2
Department of Obstetrics and Gynecology, E-Da Hospital, Kaohsiung 824, Taiwan
3
Department of Medical Science and Biotechnology, I-Shou University, Kaohsiung 824, Taiwan
4
School of Medicine, I-Shou University, Kaohsiung 824, Taiwan

Abstract

Background: Endometrial cancer remains a therapeutic challenge, particularly in advanced and recurrent cases. This study investigated the anticancer effects of three synthetic CDDO derivatives, RTA 404, RTA dh404, and RTA 408, in human endometrial cancer Ishikawa cells. Methods: Cell viability was assessed using the CCK-8 assay, while Ki67 expression, apoptosis, cell cycle distribution, mitochondrial membrane potential, and intracellular reactive oxygen species (ROS) levels were evaluated using immunofluorescence staining and flow cytometry-based assays. Results: All three CDDO derivatives reduced the viability-associated metabolic activity of Ishikawa cells and were associated with changes in Ki67 positivity, apoptosis, and cell cycle distribution. RTA 404 and RTA dh404 increased the proportion of cells in the G1 phase, whereas RTA 408 increased the G2/M-phase population. In addition, treatment with the compounds was associated with reduced mitochondrial membrane potential and decreased intracellular ROS-associated fluorescence. Conclusion: These findings demonstrate that treatment with RTA 404, RTA dh404, and RTA 408 is associated with reduced viability-associated metabolic activity, increased Annexin V positivity, altered cell-cycle distributions, and mitochondrial depolarization in Ishikawa endometrial cancer cells. Further mechanistic studies are required to determine the molecular pathways underlying these cellular responses.

1. Introduction

Endometrial cancer is the most frequently diagnosed gynecologic malignancy in many developed countries and represents a significant cause of cancer-related morbidity and mortality among women [1,2]. The majority of patients are diagnosed at an early stage and achieve favorable outcomes after surgical intervention [3]. Despite advances in the management of endometrial cancer, treatment of advanced, recurrent, or metastatic disease remains challenging, particularly in patients who develop resistance to conventional therapies [4,5]. Although platinum-based chemotherapy and immune checkpoint inhibitors have improved treatment outcomes in selected patient populations, the clinical response remains heterogeneous and is influenced by tumor molecular characteristics and mismatch repair status.
The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway has attracted considerable attention because its dysregulation contributes to tumor cell survival, proliferation, and metabolic regulation [6,7]. However, clinical responses to PI3K/AKT/mTOR pathway inhibitors have generally been variable, highlighting the complexity of pathway regulation and the potential involvement of compensatory signaling mechanisms [8]. In addition, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib, have been investigated in combination with hormonal therapy, particularly in estrogen receptor-positive endometrial cancer [9,10]. Early-phase clinical studies have demonstrated promising activity, although further validation is required to establish their clinical application. Poly (ADP-ribose) polymerase (PARP) inhibitors have also been explored in combination with immune checkpoint inhibitors or other therapeutic agents in targeting DNA damage response pathways in selected endometrial cancers [11,12]. These approaches emphasize the importance of investigating compounds capable of modulating multiple cellular processes involved in tumor survival, cell cycle regulation, and treatment response.
Exploring novel compounds capable of suppressing tumor growth and improving therapeutic strategies remains an important research priority. The initiation and progression of endometrial cancer involve complex molecular alterations that promote uncontrolled proliferation, abnormal cell cycle progression, evasion of apoptosis, and changes in cellular metabolism [13]. Cancer cells frequently maintain an altered redox balance to support rapid growth and survival [14]. Although moderate ROS levels can promote tumor-associated signaling pathways, excessive ROS accumulation can induce oxidative damage and activate cell death pathways [15,16]. Consequently, regulation of intracellular ROS homeostasis has become an important target for anticancer intervention.
Mitochondria are central regulators of cellular energy metabolism and apoptosis. Alterations in mitochondrial membrane potential (ΔΨm) represent an early event during mitochondrial-mediated apoptosis, leading to activation of downstream apoptotic pathways [17,18]. In addition, mitochondrial dysfunction is closely associated with changes in oxidative stress signaling and cellular survival mechanisms [19]. Therefore, compounds capable of modulating mitochondrial function and redox balance may provide potential strategies for inhibiting cancer cell growth.
Synthetic oleanane triterpenoids, derived from modifications of the natural triterpenoid oleanolic acid, represent a group of multifunctional compounds with reported anti-inflammatory, antioxidant, cytoprotective, and anticancer properties [20,21,22]. Previous studies have demonstrated that these compounds can regulate several molecular pathways, including Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (NRF2), nuclear factor-κB (NF-κB), and PI3K/AKT/mTOR-associated signaling [22,23,24]. Depending on the compound, concentration, and cellular context, synthetic oleanane triterpenoids have been reported to influence cellular redox homeostasis, inflammatory responses, cell cycle progression, and apoptotic signaling. Importantly, their biological effects are not necessarily restricted to antioxidant activity; at micromolar concentrations, certain CDDO derivatives have demonstrated antiproliferative and proapoptotic effects in various cancer models. These observations suggest that CDDO-derived triterpenoids may provide a useful pharmacological platform for investigating the regulation of cancer cell viability, apoptosis, mitochondrial function, and redox-associated responses [25,26,27]. Nevertheless, the effects of RTA 404, RTA dh404, and RTA 408 in endometrial cancer cells remain insufficiently characterized, providing the rationale for evaluating their biological activities in the present study.
However, despite the reported biological activities of synthetic CDDO derivatives, their effects in endometrial cancer remain poorly understood. In this study, we aimed to investigate the cellular responses of human endometrial cancer Ishikawa cells to these three CDDO derivatives. By evaluating viability-associated metabolic activity, Ki67 immunoreactivity, apoptotic cell populations, cell cycle distribution, mitochondrial membrane potential, and intracellular ROS-associated fluorescence, this study provides preliminary evidence regarding the biological effects of CDDO derivatives in endometrial cancer cells and establishes a basis for further mechanistic investigation.

2. Materials and Methods

2.1. Reagents and Chemical Preparation

Synthetic oleanane triterpenoid derivatives, including RTA 404 (CAS number: 932730-52-4), RTA dh404 (CAS number: 1191265-33-4), and RTA 408 (CAS number: 1474034-05-3), were obtained from Med Chem Express (MCE). Stock solutions of CDDO derivatives were prepared by dissolving compounds in dimethyl sulfoxide (DMSO) and stored according to the manufacturer’s instructions. Working concentrations were freshly prepared by diluting stock solutions with complete culture medium before each experiment. The final concentration of 0.1% DMSO in the culture medium was maintained at a level that did not affect cell viability. All reagents were prepared using sterile techniques.

2.2. Cell Culture

Human endometrial cancer Ishikawa cells were obtained from ECACC (Sigma-99040201, Ronkonkoma, NY, USA). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, BRL (Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, BRL (Grand Island, NY, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (P/S; Simply Biologics, Taoyuan, Taiwan). Cells were cultured at 37 °C in a humidified incubator containing 5% CO2. Before experimental treatment, cells were maintained under logarithmic growth conditions and examined regularly for morphological changes. Cell line authentication was performed using the MycoAlert™ Mycoplasma Detection Kit (Lonza, Basel, Switzerland) within three months prior to experiments.

2.3. Cell Viability Assay

Cell viability was evaluated using the Cell Counting Kit-8 (CCK-8; Dojindo Co., Tabaru, Japan) assay. Ishikawa cells were seeded into 96-well plates at a density of 3000 cells/well in 100 µL of complete culture medium and allowed to attach overnight. Cells were subsequently treated with different concentrations of RTA 404, RTA dh404, or RTA 408 for 24, 48, and 72 h. The tested concentrations were RTA 404 (0, 0.5, 1, 2 µM), RTA dh404 (0, 1, 2, 4 µM), RTA 408 (0, 0.6, 0.8, 1 µM). Following treatment, CCK-8 reagent was added to each well at 10 µL and incubated for at least 1 h at 37 °C. Absorbance was measured at 450 nm using a multi-well plate reader (Powerwave XS, Biotek). Cell viability was calculated as a percentage of the corresponding vehicle-control group. Each experimental condition was assessed using 6-well plates, and the experiments were independently repeated at least three times; the results were expressed as the mean (±SEM).

2.4. Cell Cycle Analysis

Cell cycle distribution was analyzed by propidium iodide (PI) staining followed by flow cytometry. Ishikawa cells were seeded in 6-well plates at a density of 3 × 105 and treated with RTA 404, RTA dh404, or RTA 408 at the indicated concentrations for 24 h. Cells were harvested by trypsinization, washed with phosphate-buffered saline (PBS), and fixed in cold 75% ethanol overnight at −20 °C. After fixation, cells were washed and incubated with PI staining solution containing RNase A for 30 min at room temperature in the dark. DNA content was measured using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). At least 104 events were acquired for each sample. Cell populations in the G0/G1, S, and G2/M phases were determined using WinMDI 2.8 software. All experiments were independently repeated at least three times, and the results were expressed as the mean (±SEM).

2.5. Apoptosis Assay

Apoptosis was evaluated using Annexin V-FITC and propidium iodide (PI) double staining followed by flow cytometry. Ishikawa cells were treated with RTA 404, RTA dh404, or RTA 408 for 4 and 24 h at the indicated concentrations. Following treatment, both floating and adherent cells were collected, washed with PBS, and resuspended in binding buffer. Cells were stained using an Annexin V-FITC/PI apoptosis detection kit (BD Pharmingen, San Diego, CA, USA) according to the manufacturer’s instructions. Briefly, cells were incubated with Annexin V-FITC and PI for 30 min at room temperature in the dark before flow cytometric analysis using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). At least 104 events were acquired per sample. Cell populations were classified as viable (Annexin V−/PI−), early apoptotic (Annexin V+/PI−), and late apoptotic or membrane-compromised (Annexin V+/PI+) cells. Data were analyzed using WinMDI 2.8 free software (BD, San Jose, CA, USA). All experiments were independently repeated at least three times, and the results were expressed as the mean (±SEM).

2.6. ROS Assay

Intracellular reactive oxygen species (ROS)-associated fluorescence was evaluated using a ROS detection kit (Molecular Probes, Invitrogen, Carlsbad, CA, USA). Ishikawa cells were treated with RTA 404, RTA dh404, or RTA 408 at the indicated concentrations for 24 h. Following treatment, cells were harvested, washed with PBS, and incubated with the fluorescent ROS probes supplied in the kit at 10 µM for 30 min at room temperature in the dark. After staining, cells were washed according to the manufacturer’s instructions and analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Fluorescence signals were detected using DCFH-DA. At least 104 events were acquired for each sample. Fluorescence intensity was quantified using WinMDI 2.8 software (La Jolla, CA, USA). Results were expressed relative to the vehicle-control group. All experiments were independently repeated at least three times, and the results were expressed as the mean (±SEM).

2.7. Mitochondrial Membrane Potential (MMP) Assay

Mitochondrial membrane potential (ΔΨm) was evaluated using the JC-1 fluorescent probe (Sigma, Ronkonkoma, NY, USA). Ishikawa cells were treated with RTA 404, RTA dh404, or RTA 408 at the indicated concentrations for 6 h. Following treatment, cells were collected, washed with PBS, and incubated with JC-1 staining solution at 50 µL/well for 20 min at 37 °C in the dark. Cells were subsequently washed and resuspended in the appropriate assay buffer before flow cytometric analysis. Fluorescence signals were detected using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), with green JC-1 monomer and red JC-1 aggregate fluorescence collected. At least 104 events were acquired per sample. The proportion of cells exhibiting reduced mitochondrial membrane potential was determined based on the JC-1 fluorescence distribution and quantified using WinMDI 2.8 software (La Jolla, CA, USA). All experiments were independently repeated at least three times, and the results were expressed as the mean (±SEM).

2.8. Immunocytochemistry Analysis

Ki67 expression was examined by immunofluorescence staining. Ishikawa cells were seeded onto coverslips at a density of 1 × 104 and treated with RTA 404, RTA dh404, or RTA 408 at the indicated concentrations for 24 h. Following treatment, cells were washed with PBS and fixed using 2% Fixing buffer for 15 min. Cells were subsequently permeabilized using 1x permeabilization buffer for 10 min and blocked with 5% BSA for 2 h. Samples were incubated with a primary antibody against Ki67 (1:500, ab15580; Abcam, Cambridge, UK) at 37 °C for 2 h, followed by incubation with the appropriate fluorescently labeled secondary antibody (FITC-fluor-labeled 488 nm dilution of 1:500) for 30 min in the dark. α-Tubulin (1:500, 11224-1-AP; Proteintech, Chicago, IL, USA) followed by labeled secondary antibody (Alexa Fluor 555 nm dilution of 1:500). Nuclei were counterstained with DAPI (1:1000, Invitrogen). Fluorescence images were acquired using a fluorescence microscope (3D Cell Explorer FLUO, NanoLive, Cell-Bio Biotechnology, New Taipei City, Taiwan) under identical exposure and acquisition settings for all experimental groups. Ki67 immunofluorescence was quantified using ImageJ software 1.54p. Quantitative image analysis was performed using ImageJ software. DAPI-positive nuclei were used to identify the total number of cells, and nuclei exhibiting positive Ki67 immunoreactivity were counted as Ki67-positive cells. The percentage of Ki67-positive nuclei was calculated by dividing the number of Ki67-positive nuclei by the total number of DAPI-positive nuclei and multiplying by 100. For each sample, 5 randomly selected fields were analyzed. Quantification was performed across three independent experiments.
Ki 67 − positive   nuclei   % = Number   of   Ki 67 − positive   nuclei Total   number   of   DAPI − positive   nuclei × 100

2.9. Statistical Analysis

All experiments were independently performed at least three times, and data are presented as the mean ± standard error of the mean (SEM). Statistical analyses were performed using GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA). Comparisons between two groups were conducted using Student’s t-test for normally distributed data. Comparisons between multiple groups were performed using one-way analysis of variance (ANOVA) followed by an appropriate post hoc test. A p-value of less than 0.05 was considered statistically significant.

3. Results

3.1. CDDO Derivatives Reduce Cell Viability in Endometrial Cancer Ishikawa Cells

To evaluate the effects of synthetic CDDO-derived triterpenoids on the viability of endometrial cancer cells, Ishikawa cells were treated with increasing concentrations of RTA 404, RTA dh404, or RTA 408 for 24, 48, and 72 h. Cellular responses were assessed using the Cell Counting Kit-8 (CCK-8) assay. As shown in Figure 1A,B, treatment with all three compounds resulted in concentration- and time-dependent reductions in CCK-8 signals compared with the untreated control group. These findings indicate that RTA 404, RTA dh404, and RTA 408 reduce the viability-associated metabolic activity of Ishikawa cells under the experimental conditions. The calculated IC50 values are summarized in Table S1, indicating that approximately 50% growth inhibition was achieved within the tested concentration range. Among the tested compounds, higher concentrations resulted in a more pronounced reduction in cell viability after prolonged treatment. These results demonstrate that CDDO derivatives exert a potent reduction in the viability of endometrial cancer cells.
Figure 1. Effects of CDDO derivatives on the viability-associated metabolic activity of Ishikawa cells. (A) Chemical structures of RTA 404, RTA dh404, and RTA 408. (B) Ishikawa cells were treated with different concentrations of RTA 404, RTA dh404, or RTA 408 for 24, 48, and 72 h. Cellular responses were evaluated using the CCK-8 assay. Results are expressed as percentages relative to the untreated control group. Data are presented as mean ± SEM from at least three independent experiments. The significance in the panel is represented as follows: *** p < 0.001.

3.2. CDDO Derivatives Reduce Ki67 Immunoreactivity in Ishikawa Cells

To further investigate whether the effects of CDDO derivatives on Ishikawa cells were associated with changes in proliferative activity, Ki67 expression was examined by immunofluorescence staining. Following 24-h treatment with RTA 404, RTA dh404, or RTA 408, a reduction in Ki67-positive nuclear staining was observed compared with the untreated control group (Figure 2A). Quantitative analysis was performed by determining the percentage of Ki67-positive nuclei relative to the total number of DAPI-positive nuclei using ImageJ software. As shown in Figure 2B, treatment with CDDO derivatives significantly decreased the percentage of Ki67-positive nuclei compared with the control group. These findings indicate that CDDO derivative treatment is associated with a reduction in Ki67 immunoreactivity, suggesting a decrease in the proliferative status of Ishikawa cells.
Figure 2. CDDO derivatives suppress Ki67 expression in Ishikawa cells. (A) Representative immunofluorescence images showing Ki67 expression in Ishikawa cells treated with RTA 404, RTA dh404, or RTA 408 for 24 h. The subcellular localization of Ki67 immunoreactivity was revealed by nucleoli with FITC Fluor 488-conjugated goat anti-mouse secondary antibody, and α-Tubulin was stained for microtubules with Alexa Fluor 555-conjugated donkey anti-rabbit. Nuclei were counterstained with DAPI. (B) Quantification of the percentage of Ki67-positive nuclei among total DAPI-positive nuclei in Ishikawa cells following treatment with RTA 404, RTA dh404, or RTA 408 for 24 h. Data are presented as mean ± SEM from three independent experiments. * p < 0.05, ** p < 0.01 versus control.

3.3. CDDO Derivatives Induce Apoptotic Cell Death in Ishikawa Cells

To determine whether CDDO derivatives affect programmed cell death, Annexin V-FITC/PI staining was performed followed by flow cytometric analysis. Treatment with RTA 404, RTA dh404, or RTA 408 increased the proportion of Annexin V-positive cells compared with the control group at both 4 and 24 h (Figure 3A). Quantification of apoptotic populations demonstrated that CDDO derivative treatment promoted apoptosis in Ishikawa cells (Figure 3B). These results suggest that induction of apoptosis contributes to the anti-tumor activity of CDDO derivatives.
Figure 3. CDDO derivatives induce apoptosis in Ishikawa cells. (A) Representative flow cytometry dot plots of Annexin V-FITC/PI staining in Ishikawa cells following treatment with RTA 404, RTA dh404, or RTA 408 for 4 and 24 h. (B) Quantitative analysis of apoptotic cell populations. Results are presented as mean ± SEM from three independent experiments. * p < 0.05, ** p < 0.01, **** p < 0.0001 versus control.

3.4. CDDO Derivatives Alter Cell Cycle Progression in Ishikawa Cells

To examine whether CDDO derivatives affect cell cycle regulation, Ishikawa cells were treated with RTA 404, RTA dh404, or RTA 408 for 24 h and analyzed by propidium iodide staining and flow cytometry. As shown in Figure 4A, treatment with RTA 404 and RTA dh404 resulted in an increased proportion of cells in the G1 phase accompanied by a reduction in the G2/M population. In contrast, RTA 408 treatment caused an accumulation of cells in the G2/M phase with a corresponding decrease in the G1 population. Quantitative analysis confirmed significant alterations in cell cycle distribution following CDDO derivative exposure (Figure 4B). These findings indicate that CDDO derivatives inhibit Ishikawa cell proliferation through modulation of cell cycle progression.
Figure 4. CDDO derivatives regulate cell cycle progression in Ishikawa cells. (A) Representative flow cytometry histograms showing cell cycle distribution after treatment with RTA 404, RTA dh404, or RTA 408 for 24 h. (B) Quantification of cell populations in G0/G1, S, and G2/M phases. Data are expressed as mean ± SEM from three independent experiments. * p < 0.05 versus control.

3.5. CDDO Derivatives Disrupt Mitochondrial Membrane Potential in Ishikawa Cells

Mitochondrial membrane potential (ΔΨm) was evaluated using JC-1 staining to investigate whether CDDO derivative treatment was associated with changes in mitochondrial function. Compared with untreated cells, Ishikawa cells treated with RTA 404, RTA dh404, or RTA 408 showed increased JC-1 monomer fluorescence and reduced JC-1 aggregate formation (Figure 5A), consistent with mitochondrial membrane depolarization. Quantitative analysis further demonstrated an increased proportion of cells with reduced ΔΨm following treatment (Figure 5B). These findings indicate that CDDO derivative exposure is associated with a reduction in mitochondrial membrane potential. However, the present results do not establish whether mitochondrial depolarization precedes or directly contributes to apoptosis.
Figure 5. CDDO derivatives induce mitochondrial membrane depolarization in Ishikawa cells. (A) Representative JC-1 staining profiles showing mitochondrial membrane potential changes following CDDO derivative treatment. Increased green fluorescence indicates mitochondrial depolarization. (B) Quantitative analysis of cells with reduced mitochondrial membrane potential. Data represent mean ± SEM from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 versus control.

3.6. CDDO Derivatives Decrease Intracellular ROS Levels in Ishikawa Cells

Intracellular ROS-associated fluorescence was evaluated using a ROS-sensitive fluorescent probe and flow cytometry. Following treatment with RTA 404, RTA dh404, or RTA 408, Ishikawa cells exhibited reduced fluorescence signals compared with untreated control cells (Figure 6A,B). These findings indicate that treatment with the CDDO derivatives was associated with a decrease in the fluorescence signal detected by the ROS-sensitive probe under the experimental conditions.
Figure 6. CDDO derivatives reduce intracellular ROS levels in Ishikawa cells. (A) Representative flow cytometry profiles showing intracellular ROS production after treatment with RTA 404, RTA dh404, or RTA 408. (B) Quantification of ROS fluorescence intensity. Data are presented as mean ± SEM from three independent experiments. * p < 0.05 versus control.

4. Discussion

Endometrial cancer remains a major gynecological malignancy, and the development of novel therapeutic strategies is required, particularly for patients with advanced-stage disease or limited treatment responses. In this study, we investigated the biological effects of three synthetic oleanane triterpenoid derivatives, RTA 404, RTA dh404, and RTA 408, in human endometrial cancer Ishikawa cells. Our findings showed that treatment with these CDDO derivatives was associated with reduced CCK-8 viability signals (Figure 1), decreased Ki67 expression (Figure 2), increased Annexin V-positive cell populations (Figure 3), altered cell-cycle distributions (Figure 4), mitochondrial membrane depolarization (Figure 5), and reduced intracellular ROS-associated fluorescence (Figure 6). Notably, RTA 404 and RTA dh404 were associated with increased G1-phase accumulation, whereas RTA 408 was associated with increased G2/M-phase accumulation. Collectively, these findings indicate that CDDO derivative treatment is accompanied by multiple cellular changes related to viability, apoptosis, cell-cycle progression, mitochondrial function, and intracellular redox status in Ishikawa cells. However, the current findings have not established a direct causal relationship between these cellular responses, nor have they identified the specific molecular pathways leading to the observed effects.
Uncontrolled cellular proliferation is a fundamental characteristic of cancer progression. In the present study, the CCK-8 assay showed that RTA 404, RTA dh404, and RTA 408 reduced the viability-associated metabolic activity of Ishikawa cells in a concentration- and time-dependent manner (Figure 1). However, CCK-8 is based on cellular dehydrogenase activity and therefore does not directly measure cell division or cell number. Because the tested CDDO derivatives are associated with the regulation of cellular redox signaling and mitochondrial function, changes in cellular metabolic activity may contribute to the observed reduction in CCK-8 signals independently of changes in cell number. Consistent with these findings, immunofluorescence analysis demonstrated a decreased proportion of Ki67-positive nuclei following CDDO derivative treatment, suggesting an alteration in the proliferative status of Ishikawa cells (Figure 2). Nevertheless, reduced Ki67 positivity alone cannot establish that cell proliferation is directly inhibited or exclude the contribution of cytotoxic effects. In addition, the increased apoptotic cell population observed following treatment indicates that apoptosis may contribute to the reduction in cell viability. Therefore, the combined findings suggest that CDDO derivatives affect Ishikawa cell viability through multiple cellular responses, including alterations in metabolic activity, Ki67 expression, cell cycle distribution, and apoptosis. Further validation using direct cell-number measurements, DNA synthesis assays such as EdU incorporation, or clonogenic assays, together with compound-only and cell-free CCK-8 controls, will be necessary to distinguish direct antiproliferative effects from metabolic or cytotoxic responses.
Cell cycle dysregulation plays an essential role in tumor development by allowing continuous cancer cell proliferation [28]. In our results, flow cytometric analysis demonstrated that different CDDO derivatives induced distinct alterations in cell cycle distribution. RTA 404 and RTA dh404 treatment resulted in increased G1 phase accumulation, suggesting inhibition of the G1/S transition. In contrast, RTA 408 promoted G2/M phase arrest, indicating that individual CDDO derivatives may regulate cell cycle progression through distinct molecular mechanisms (Figure 4). Previous studies have reported that synthetic triterpenoids can modulate cell cycle-related proteins, including cyclins and cyclin-dependent kinase regulators, which may contribute to their antiproliferative effects [29,30]. Further investigation of specific cell cycle regulatory molecules will be required to clarify the precise mechanisms involved in Ishikawa cells.
An additional consideration in interpreting the biological activities of these compounds is their structural diversity, which may contribute to differences in their cellular responses. RTA 404 and RTA dh404 share a closely related synthetic oleanane triterpenoid scaffold and a trifluoroethyl amide substituent, but differ in the saturation state of the 9,11 positions [29]. In contrast, RTA 408 possesses a distinct 28-noroleanane scaffold and a difluoropropanamide substituent, representing a different structural modification within the CDDO-derived triterpenoid family [29]. These structural differences provide a basis for exploring potential relationships between chemical modifications and biological responses.
Interestingly, although all three compounds reduced CCK-8 viability-associated signals, decreased Ki67 immunoreactivity, increased apoptotic cell populations, and altered mitochondrial membrane potential and ROS-associated fluorescence, their effects on cell cycle distribution were distinct. RTA 404 and RTA dh404 predominantly induced G1-phase accumulation, whereas RTA 408 promoted G2/M-phase accumulation. These observations raise the possibility that differences in the triterpenoid scaffold, saturation state, and amide substituents may be associated with compound-specific effects on cell cycle regulation.
However, because the present study included only three derivatives and did not investigate their direct molecular targets or systematically evaluate additional structural analogues, a definitive structure–activity relationship cannot yet be established. Further comparative studies using structurally related derivatives and molecular analyses of cell cycle regulatory pathways are warranted to clarify how specific chemical modifications influence the biological activities of CDDO-derived triterpenoids.
Apoptosis is a major mechanism involved in the elimination of cancer cells and is frequently targeted by anticancer compounds [31]. In the present study, Annexin V-FITC/PI staining demonstrated an increased proportion of apoptotic cells following treatment with RTA 404, RTA dh404, and RTA 408 (Figure 3). In parallel, JC-1 staining revealed a reduction in mitochondrial membrane potential in treated Ishikawa cells (Figure 5). These findings indicate that CDDO derivative treatment is associated with both apoptotic responses and mitochondrial membrane depolarization. However, although mitochondrial depolarization is commonly observed during apoptosis, the present experiments do not establish whether mitochondrial alterations occur upstream of apoptosis or directly mediate the apoptotic response. Additional investigations involving mitochondrial apoptotic regulators, such as BAX, BCL-2, cytochrome c, and caspase-9, together with time-course analyses and functional perturbation experiments, will be necessary to determine the contribution of mitochondrial signaling to CDDO derivative-induced apoptosis.
Oxidative stress is closely associated with cancer cell survival, metabolism, and therapeutic responses [32]. Although increased ROS accumulation can promote oxidative damage and apoptosis in cancer cells, the biological effects of ROS depend on their intracellular concentration, subcellular localization, and cellular context [33]. In this study, treatment with RTA 404, RTA dh404, and RTA 408 resulted in decreased ROS-associated fluorescence in Ishikawa cells (Figure 6). This finding suggests that the tested compounds alter the intracellular redox-associated fluorescence profile under the experimental conditions. Nevertheless, reduced ROS-associated fluorescence does not demonstrate that the observed apoptotic response is independent of ROS. Changes in probe fluorescence may reflect alterations in cellular redox status and should not be interpreted as direct evidence of a specific antioxidant signaling mechanism.
CDDO derivatives have previously been reported to interact with the KEAP1–Nrf2 signaling pathway, which plays an important role in antioxidant defense and redox homeostasis [23,29,34]. In particular, RTA 408 has been described as an Nrf2 activator in non-cancer experimental models [35]. However, Nrf2 activation, KEAP1 regulation, and downstream antioxidant responses were not directly examined in the present study. Therefore, it remains unclear whether the observed decrease in ROS-associated fluorescence following CDDO derivative treatment is related to KEAP1–Nrf2 signaling or other cellular processes. Furthermore, the current findings do not establish a causal relationship between changes in ROS-associated fluorescence, mitochondrial membrane potential, and apoptosis. Future studies should directly evaluate Nrf2 nuclear translocation, KEAP1 expression, and downstream antioxidant proteins, including HO-1 and NQO1. Functional approaches, such as Nrf2 knockdown or pharmacological inhibition, combined with ROS modulation experiments, will be important to determine whether these signaling pathways contribute to the cellular responses induced by CDDO derivatives.
Several limitations should be acknowledged. First, this study was performed using only one endometrial cancer cell line, and additional models, including other endometrial cancer subtypes and in vivo models, are required to validate these findings. Second, although we demonstrated changes in mitochondrial function and ROS levels, the upstream molecular pathways responsible for these effects remain unclear. However, the selectivity indices (SIs) of RTA 404, RTA dh404, and RTA 408 could not be determined because normal human endometrial epithelial cells were not included as a non-malignant control model. The SI is generally calculated as the ratio of the IC50 in normal cells to that in cancer cells and provides an indication of the relative cytotoxic selectivity of a compound toward malignant cells [36]. Although the present findings demonstrate that these CDDO-derived triterpenoids affect cell viability-associated metabolic activity, apoptosis, and cell-cycle progression in Ishikawa endometrial cancer cells, they do not establish whether these effects are preferentially directed toward malignant cells. Therefore, further investigations using normal human endometrial epithelial cells are warranted to determine the SIs of these compounds and clarify their potential therapeutic selectivity.

5. Conclusions

In conclusion, this study demonstrates that treatment with RTA 404, RTA dh404, and RTA 408 is associated with reduced CCK-8 viability signals and Ki67 expression, increased Annexin V-positive cell populations, altered cell-cycle distributions, and mitochondrial membrane depolarization in Ishikawa endometrial cancer cells. Although the three CDDO derivatives exhibited distinct cell-cycle distribution patterns, with RTA 404 and RTA dh404 associated with G1-phase accumulation and RTA 408 associated with G2/M-phase accumulation, the molecular mechanisms underlying these differences remain to be elucidated. Further studies involving molecular pathway analyses and functional validation are needed to clarify the mechanisms responsible for these cellular responses and to evaluate the therapeutic potential of these compounds in endometrial cancer.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cimb48111224/s1.

Author Contributions

Conceptualization and design of the study: K.-T.L.; data collection: Y.-S.Y.; statistical and Biostatistical analysis of data: K.-T.L. and C.-Y.W.; writing—original draft: K.-T.L. and Y.-C.H.; writing—review and/or revision of the manuscript: K.-T.L. and Y.-C.H.; supervision and validation: Y.-C.H. and C.-Y.C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by I-Shou University (grant no. ISU-109-IUC-01, ISU-111-IUC-08, ISU-114-01-09A) and E-Da Hospital (grant no. EDAHI115002).

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Acknowledgments

We thank the students of the Department of Medical Science and Biotechnology at I-Shou University for providing the research technology.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Tang, W.-Z.; Cai, Q.-Y.; Huang, K.-J.; Xu, W.-Z.; Li, J.-Z.; Pan, Y.-R.; Xu, H.-Y.; Zhao, Y.-F.; Sheng, T.-H.; Li, Z.-M.; et al. The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021. BMC Public Health 2025, 25, 1774. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Crosbie, E.J.; Kitson, S.J.; McAlpine, J.N.; Mukhopadhyay, A.; Powell, M.E.; Singh, N. Endometrial cancer. Lancet 2022, 399, 1412–1428. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Baker-Rand, H.; Kitson, S.J. Recent advances in endometrial cancer prevention, early diagnosis and treatment. Cancers 2024, 16, 1028. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Matoba, Y.; Devins, K.M.; Milane, L.; Manning, W.B.; Mazina, V.; Yeku, O.O.; Rueda, B.R. High-grade endometrial cancer: Molecular subtypes, current challenges, and treatment options. Reprod. Sci. 2024, 31, 2541–2559. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Gordhandas, S.; Zammarrelli, W.A.; Rios-Doria, E.V.; Green, A.K.; Makker, V. Current evidence-based systemic therapy for advanced and recurrent endometrial cancer. J. Natl. Compr. Cancer Netw. 2023, 21, 217–226. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Glaviano, A.; Foo, A.S.; Lam, H.Y.; Yap, K.C.; Jacot, W.; Jones, R.H.; Eng, H.; Nair, M.G.; Makvandi, P.; Geoerger, B. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 2023, 22, 138. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Jiang, M.; Zhang, K.; Zhang, Z.; Zeng, X.; Huang, Z.; Qin, P.; Xie, Z.; Cai, X.; Ashrafizadeh, M.; Tian, Y. PI3K/AKT/mTOR axis in cancer: From pathogenesis to treatment. MedComm 2025, 6, e70295. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Darici, S.; Alkhaldi, H.; Horne, G.; Jørgensen, H.G.; Marmiroli, S.; Huang, X. Targeting PI3K/Akt/mTOR in AML: Rationale and clinical evidence. J. Clin. Med. 2020, 9, 2934. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Ray-Coquard, I.; Monk, B.J.; Lorusso, D.; Mahdi, H.; Upadhyay, V.; Graul, R.; Husain, A.; Mirza, M.R.; Slomovitz, B. The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma. Int. J. Gynecol. Cancer 2023, 33, 1943–1949. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. How, J.A.; Westin, S.N.; Pham, M.; Lawson, B.; Chen, M.; Tandon, N.; Yuan, Y.; Zhang, R.; Jazaeri, A.A.; Sood, A.K. Efficacy of everolimus and letrozole with or without ribociclib in recurrent endometrial cancer: A phase 2 randomized clinical trial. Nat. Commun. 2026, 17, 10413. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Pham, M.M.; Ngoi, N.Y.; Peng, G.; Tan, D.S.; Yap, T.A. Development of poly (ADP-ribose) polymerase inhibitor and immunotherapy combinations: Progress, pitfalls, and promises. Trends Cancer 2021, 7, 958–970. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Pilié, P.G.; Tang, C.; Mills, G.B.; Yap, T.A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 2019, 16, 81–104. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Balhara, N.; Yadav, R.; Chauhan, M.B. Role of signaling pathways in endometrial cancer. Mol. Biol. Rep. 2025, 52, 408. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Zhao, Y.; Ye, X.; Xiong, Z.; Ihsan, A.; Ares, I.; Martínez, M.; Lopez-Torres, B.; Martínez-Larrañaga, M.-R.; Anadón, A.; Wang, X. Cancer metabolism: The role of ROS in DNA damage and induction of apoptosis in cancer cells. Metabolites 2023, 13, 796. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Akter, S.; Madhuvilakku, R.; Kar, A.K.; Nila, I.S.; Liu, P.; Inuzuka, H.; Wei, W.; Hong, Y.J.S. Reactive oxygen species (ROS) in cancer: From mechanism to therapeutic implications. Signal Transduct. Target. Ther. 2026, 11, 111. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Nigam, M.; Punia, B.; Dimri, D.B.; Mishra, A.P.; Radu, A.-F.; Bungau, G. Reactive oxygen species: A double-edged sword in the modulation of cancer signaling pathway dynamics. Cells 2025, 14, 1207. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Feng, Y.; Wang, Y.; Jiang, C.; Fang, Z.; Zhang, Z.; Lin, X.; Sun, L.; Jiang, W. Nicotinamide induces mitochondrial-mediated apoptosis through oxidative stress in human cervical cancer HeLa cells. Life Sci. 2017, 181, 62–69. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Patwardhan, G.A.; Beverly, L.J.; Siskind, L.J. Sphingolipids and mitochondrial apoptosis. J. Bioenerg. Biomembr. 2016, 48, 153–168. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. Barbour, J.A.; Turner, N. Mitochondrial stress signaling promotes cellular adaptations. Int. J. Cell Biol. 2014, 2014, 156020. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Borella, R.; Forti, L.; Gibellini, L.; De Gaetano, A.; De Biasi, S.; Nasi, M.; Cossarizza, A.; Pinti, M. Synthesis and anticancer activity of CDDO and CDDO-Me, two derivatives of natural triterpenoids. Molecules 2019, 24, 4097. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Demir, N.; Ciftci, H.; Elamin, K.M.; Can, M.; Sever, B. Design, Synthesis and Biological Evaluation of Novel Oleanolic Acid Derivatives as Potential Anti-Leukemic Agents. Life 2026, 16, 1335. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Li, W.; Wang, M.; Du, P.; Han, A.; Feng, X.; Chen, L. CDDO-Me triggers ROS-dependent ferroptosis and apoptosis in cervical cancer via targeting PI3K/Nrf2 pathway. Food Chem. Toxicol. 2025, 204, 115664. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Kim, J.-E.; Park, H.; Kang, T.-C. CDDO-Me distinctly regulates regional specific astroglial responses to status epilepticus via ERK1/2-Nrf2, PTEN-PI3K-AKT and NFκB signaling pathways. Antioxidants 2020, 9, 1026. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Wang, X.-Y.; Zhang, X.-H.; Peng, L.; Liu, Z.; Yang, Y.-X.; He, Z.-X.; Dang, H.-W.; Zhou, S.-F. Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells. Am. J. Transl. Res. 2017, 9, 4652. [Google Scholar] [PubMed]
  25. Tsai, T.-H.; Lieu, A.-S.; Wang, Y.-W.; Yang, S.-F.; Hsu, Y.-C.; Lin, C.-L. Therapeutic potential of RTA 404 in human brain malignant glioma cell lines via cell cycle arrest via p21/AKT signaling. BioMed Res. Int. 2021, 2021, 5552226. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Aminzadeh, M.A.; Reisman, S.A.; Vaziri, N.D.; Shelkovnikov, S.; Farzaneh, S.H.; Khazaeli, M.; Meyer, C.J. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease. Redox Biol. 2013, 1, 527–531. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Lee, K.-T.; Lieu, A.-S.; Lin, C.-L.; Hsu, Y.-C.; Tsai, T.-H. Synthetic oleanolic acid derivative, RTA-408, overcome in TMZ-resistant glioblastoma cells by inducing apoptosis and G1 cell cycle arrest. Med. Oncol. 2025, 42, 353. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Jamasbi, E.; Hamelian, M.; Hossain, M.A.; Varmira, K. The cell cycle, cancer development and therapy. Mol. Biol. Rep. 2022, 49, 10875–10883. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Tsai, T.-H.; Su, Y.-F.; Tsai, C.-Y.; Wu, C.-H.; Lee, K.-T.; Hsu, Y.-C. RTA dh404 induces cell cycle arrest, apoptosis, and autophagy in glioblastoma cells. Int. J. Mol. Sci. 2023, 24, 4006. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Tsai, T.-H.; Lieu, A.-S.; Huang, T.-Y.; Kwan, A.-L.; Lin, C.-L.; Hsu, Y.-C. Induction of mitosis delay and apoptosis by CDDO-TFEA in glioblastoma multiforme. Front. Pharmacol. 2021, 12, 756228. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Carneiro, B.A.; El-Deiry, W.S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 2020, 17, 395–417. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Arfin, S.; Jha, N.K.; Jha, S.K.; Kesari, K.K.; Ruokolainen, J.; Roychoudhury, S.; Rathi, B.; Kumar, D. Oxidative stress in cancer cell metabolism. Antioxidants 2021, 10, 642. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Sies, H.; Jones, D.P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell Biol. 2020, 21, 363–383. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Meng, X.; Waddington, J.C.; Tailor, A.; Lister, A.; Hamlett, J.; Berry, N.; Park, B.K.; Sporn, M.B. CDDO-imidazolide targets multiple amino acid residues on the Nrf2 adaptor, Keap1. J. Med. Chem. 2020, 63, 9965–9976. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Han, P.; Qin, Z.; Tang, J.; Xu, Z.; Li, R.; Jiang, X.; Yang, C.; Xing, Q.; Qi, X.; Tang, M.; et al. RTA-408 protects kidney from ischemia-reperfusion injury in mice via activating Nrf2 and downstream GSH biosynthesis gene. Oxidative Med. Cell Longev. 2017, 2017, 7612182. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Demirgan, R.; KaragÃ, A.; Pekmez, M.; Artun, F.T.; Mat, A. In vitro anticancer activity and cytotoxicity of some papaver alkaloids on cancer and normal cell lines. Afr. J. Tradit. Complement. Altern. Med. 2016, 13, 22–26. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.